The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Can CAR T-cells be optimised to safely treat MM patients?
Rakesh Popat, MD, PhD, from University College London, London, UK, talks to us about the potential of applying CAR T-cell therapy to treat multiple myeloma (MM). Here, he references abstracts presented at EHA by two companies, Bluebird Bio and Nanjing Legend Biotech, who have investigated their CAR T-cell constructs in patients with relapsed MM in clinical trials and achieved impressive results, namely a 100% response rate in all patients (NCT02658929) (NCT03090659). He also talks about his team’s own CAR T-cell construct, which he hopes will be more specific and potent than other CAR T-cells and also safer due to its built in ‘safety switch.’ This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
